Really nice results from transgenes' mature data on Phase IIb clinical trials using Virax' co-X-gene tech. Mature data shows the primary endpoint of progression-free survival (PFS) was met and the overall survival data suggests a clinically meaningful improvement.
Great news for the patients (in the experimental treatment group, at least), Transgene and hopefully Virax. Fingers crossed this lures a new partner for Transgene to progress to Phase III trials.
http://online.wsj.com/article/PR-CO-20140527-908891.html
Really nice results from transgenes' mature data on Phase IIb...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
2.8¢ |
Change
0.002(7.69%) |
Mkt cap ! $48.11M | |||
| Open | High | Low | Value | Volume |
| 2.7¢ | 2.8¢ | 2.7¢ | $44.61K | 1.648M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 579398 | 2.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.8¢ | 2318208 | 1 |
View Market Depth
| Last trade - 15.52pm 29/07/2025 (20 minute delay) ? |
| VHL (ASX) Chart |